Loading…
Live market data via Yahoo Finance · updated 7/31/2026
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor, Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, and NVL-330, a brain-penetrant HER2-selective inhibitor designed to treat HER2ex20-driven tumors.
Nuvalent has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Nuvalent, Inc. (NUVL) operates in the healthcare space, focused on cancer therapies. The current price is $123.83, and the market cap is $9.8B, with a market position ranked at 929.
The near-term outlook reflects a neutral to bullish trajectory in the forecast horizon, starting with a 2026 average of $123.83 and a 2026 range from $88.49 to $163.40. The longer-range forecast points to substantial upside, including a 2030 average of $233.84 and a 2050 average of $1,130.43, with corresponding max values of $318.76 and $1,848.36 respectively.
A major floor 38.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 19.1% above — clearing it would confirm fresh momentum.
Key NUVL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NUVL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $123.96 | Buy | $123.95 | Buy |
| MA 10 | $123.92 | Buy | $123.82 | Buy |
| MA 20 | $123.76 | Buy | $122.42 | Buy |
| MA 50 | $113.92 | Buy | $116.54 | Buy |
| MA 100 | $107.85 | Buy | $110.83 | Buy |
| MA 200 | $104.24 | Buy | $103.93 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.59 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 80.83 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.73 | Sell |
| ROC (12) | 0.19 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 5.13 | Buy |
| Ultimate (7,14,28) | 95.96 | Sell |
| Momentum (10) | 0.19 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 123.97 | Sell |
| ADX (14) | 32.58 | Buy |
| ATR (14) | 0.66 | Info |
The 30-day technical picture leans bullish with a bullish sentiment reading. The RSI(14) is 70, and both the 50-day and 200-day simple moving averages stand at $110.75 and $102.76 respectively. The price sits above a support level of $88.49 and below a resistance level of $123.90. The 30-day price range spans from $111.03 to $138.10.
See what a past investment in NUVLwould be worth at today's price.
$1,000 invested in NUVL on Jul 21, 2025 (≈ 12.127092 NUVL) would be worth
$1,503.27
+$503.27 (+50.3%) today · 1.50× · US Dollar
Based on a NUVL entry price of $82.46 vs. today's $123.96.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $123.96 | $1,000 | +0.0% |
| 1 month ago | $123.42 | $1,004.38 | +0.4% |
| 3 months ago | $108.85 | $1,138.81 | +13.9% |
| 6 months ago | $111.99 | $1,106.88 | +10.7% |
| 1 year ago | $82.46 | $1,503.27 | +50.3% |
| All time (5.0y) ago | $21.91 | $5,657.69 | +465.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Longer-term projections show a rising trajectory across key milestones. The 2026 forecast carries an average price of $123.83 with a min of $88.49 and a max of $163.40, yielding a neutral sentiment. From 2027 onward, the model envisions steadily higher averages and robust upside: 2027 avg $146.39 with ROI 18.2%, 2028 avg $161.03 with ROI 30%, 2029 avg $185.20 with ROI 49.6%, 2030 avg $233.84 with ROI 88.8%, 2031 avg $259.79 with ROI 109.8%, 2032 avg $270.03 with ROI 118.1%, 2033 avg $301.97 with ROI 143.9%, 2034 avg $312.96 with ROI 152.7%, 2035 avg $334.59 with ROI 170.2%, then 2040 avg $507.78 with ROI 310.1%, and 2050 avg $1,130.43 with ROI 812.9%.
These figures imply substantial upside over time, though they are estimates and not guarantees. The published path emphasizes a bullish long-term view, tempered by inherent forecasting uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average of $233.84 with a min of $182.65 and a max of $318.76, corresponding to an ROI of 88.8% along a bullish outlook.
Forecasts project positive returns starting in 2027 (ROI 18.2%), rising through 2028 (ROI 30%), 2029 (ROI 49.6%), 2030 (ROI 88.8%), 2031 (ROI 109.8%), 2032 (ROI 118.1%), 2033 (ROI 143.9%), 2034 (ROI 152.7%), 2035 (ROI 170.2%), then 2040 (ROI 310.1%), and 2050 (ROI 812.9%). These are estimates, not guarantees.
Yes. The 2030 max is $318.76, which exceeds $300, while the 2030 average is $233.84.
Current price is $123.83 and market cap is $9.8B; the rank is 929.
The 30-day technical picture is bullish with RSI(14) at 70. The SMA50 is $110.75 and the SMA200 is $102.76. Support is at $88.49 and resistance at $123.90, with a 30-day range of $111.03 to $138.10.
Nuvalent Inc Community Discussion
0Share your Nuvalent Inc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.